Since binding of PD1 to PD-L1 suppresses effector T cell activation and induces T cell exhaustion, blockade of this pathway using anti-PD1/PD-L1 antibodies can reactivate T cells and restore their effector functions, thus enhancing the anti-tumor immunity [16]. This evidence concerns the gene CD274 and neoplasm.